News Releases

Date Title and Summary View
May 17, 2022
– “Sebetralstat” Approved by WHO and USAN – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 17, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease...
Additional Formats
April 11, 2022
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 11, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will be...
Additional Formats
April 4, 2022
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 4, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 7,000 shares of...
Additional Formats
March 22, 2022
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 22, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the publication...
Additional Formats
March 10, 2022
– KVD900 Phase 3 KONFIDENT Trial Initiated – – KVD824 Phase 2 KOMPLETE Clinical Trial Enrollment on Track – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 10, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery,...
Additional Formats
March 7, 2022
-KONFIDENT to Evaluate KVD900 As First Oral On-Demand Therapy for HAE- -KONFIDENT Designed to Support Broad Label for Treatment of All HAE Attacks- CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 7, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical...
Additional Formats
March 3, 2022
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 3, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 5,000 shares of...
Additional Formats
February 28, 2022
– KVD900 Phase 2 data presented at the American Academy of Allergy , Asthma & Immunology (AAAAI) Annual Scientific Meeting – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 28, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the...
Additional Formats
February 3, 2022
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 3, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a...
Additional Formats
February 2, 2022
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 2, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that new data on...
Additional Formats
Displaying 1 - 10 of 13